KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients.

Ajit P Limaye, Marta Crespo, Nassim Kamar, Atul Humar, Robert P Carroll, Marcus R Pereira, Natalya Broyde, Weiwen Wang, Barbara Haber

Clin Infect Dis 82(2) e316-e324

PMID41321121
PMCIDPMC13016965
DOI10.1093/cid/ciaf632
发表日期2025-12-01
入排依据:未发现恶性肿瘤人群证据。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 6 张 PMC Figure,均未识别为 KM 图:Graphical Abstract:非 KM 图;Figure 1.:研究设计图;Figure 2.:非 KM 图;Figure 3.:AI 判定为 other;Figure 4.:非 KM 图;另有 1 张未列出。
摘要

摘要

BACKGROUND: QuantiFERON-cytomegalovirus (QFT-CMV) is a standardized assay for the evaluation of cytomegalovirus-specific cell-mediated immunity (CMV-CMI). OBJECTIVES: The purpose of this study was to assess the evolution of CMV-CMI posttransplant and the clinical utility of QFT-CMV for the prediction of postprophylaxis CMV disease in CMV-seronegative recipients of CMV-seropositive donor kidneys (D+R- KTRs). METHODS: 601 adult CMV D+R- kidney transplant recipients (KTRs) received letermovir or valganciclovir prophylaxis for 28 weeks in a phase 3, double-blind, multicenter trial (ClinicalTrials.gov NCT03443869). QFT-CMV was performed at a central laboratory by masked personnel at transplant, 12, 28, and 52 weeks posttransplant. Investigators assessed CMV disease through week 52. Sensitivity, specificity, and positive and negative predictive values (PPV, NPV) at week 28 were used to evaluate the clinical utility of QFT-CMV. RESULTS: Positive QFT-CMV results (pooled) were detected: baseline-1.2%, week 12-2.6%, week 28-7.7%, and week 52-28.9%. The distribution of positive results with letermovir and valganciclovir was comparable, except at week 28 (letermovir 2.2% and valganciclovir 12.8%). Postprophylaxis CMV disease by week 52 occurred in 18.3% (84/460) of evaluable participants: 12.5% (4/32) of participants with a positive, 17.5% (66/377) with a negative, and 27.5% (14/51) with an indeterminate result at week 28 (p = not significant for all comparisons). QFT-CMV sensitivity, specificity, PPV, and NPV were 8.3%, 94.3%, 87.5%, and 17.5%, and were similar when pooling indeterminate and negative results and within the letermovir and valganciclovir study arms. CONCLUSIONS: Among adult CMV high-risk D+R- KTRs who received prophylaxis, CMV-CMI by QFT-CMV increased over time. The result at the end of prophylaxis had limited clinical utility for identifying the risk for subsequent CMV disease.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(6,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Graphical Abstract无图注
非 KM Figure
Figure 1.Study design. a Stratified by receipt of ≥1 of the following lymphocyte-depleting agent(s) at the time of transplant: horse-derived or rabbit-derived antithymocyte globulin, alemtuzumab, or muromonab CD3. b Participants had to receive ≥1 dose of study regimen and be CMV D+R– and negative for CMV DNAemia on day 1 to be included; 3 participants were excluded from the letermovir arm (1 was CMV D+R+ and 2 had CMV DNAemia on day 1). Abbreviations: CMV, cytomegalovirus; D+, seropositive donor; IR, investigator–reported; R–, seronegative recipient.
非 KM Figure
Figure 2.Participant disposition. a Stratified by receipt of ≥1 of the following lymphocyte-depleting agent(s) at the time of transplant: horse-derived or rabbit-derived antithymocyte globulin, alemtuzumab, or muromonab CD3. b Participants excluded because they developed IR CMV disease prior to week 28. Abbreviations: CMV, cytomegalovirus; IR, investigator-reported.
非 KM Figure
Figure 3.QuantiFERON-CMV results over time in the total population.
非 KM Figure
Figure 4.QuantiFERON-CMV results over time by study arm.
非 KM Figure
Figure 5.QuantiFERON-CMV assay results at week 28 in the total population and investigator-reported postprophylaxis CMV disease by week 52. Chi square test with two-tailed P -value for positive versus negative results and positive versus pooled negative and indeterminate results.
非 KM Figure